上市公司资料
 
上海复星医药(集团)股份有限公司 股票代号:  02196
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 集团网址: http://www.fosunpharma.com
损益表
  2025/12
RMB(K$)
变动 2024/12
RMB(K$)
2023/12
RMB(K$)
营业额41,498,3251.438%40,909,87841,248,505
经营溢利/(亏损)3,188,00526.236%2,525,4421,092,059
特殊项目--------
摊占联营公司及共同控制公司溢利/(亏损)1,923,97917.042%1,643,8392,184,849
税前溢利/(亏损)5,111,98422.611%4,169,2813,276,908
税项(864,054)--(656,841)(369,504)
少数股东权益(877,368)--(742,554)(508,798)
股东应占溢利/(亏损)3,370,56221.686%2,769,8862,398,606
 
净利息收入/(支出)(964,847)--(1,058,705)(961,186)
折旧与摊销3,847,99018.687%3,242,1463,202,753
董事酬金----21,28448,086
 
每股盈利/(亏损)(仙)127.00022.115%104.00090.000
每股派息(仙)39.00021.875%32.00027.000
 
派息比率(%)30.709%--30.769%30.000%
每股帐面资产净值($)18.4513.859%17.76617.081
主要财务比率
  2025/12
RMB(K$)
变动 2024/12
RMB(K$)
2023/12
RMB(K$)
经营边际利润率(%)7.682%--6.173%2.648%
利息盈利率(x)5.040--3.9123.473
资产回报率(%)2.839%--2.400%2.175%
股东资金回报率(%)7.027%--5.965%5.320%

 

Copyright © 2026 ET Net Limited. All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.